Evidence map›Paper›PMID 40494510›Full record

ArticleAnalytical chemistry2025

The Structural Fingerprint of Therapeutic Monoclonal Antibodies Determined Using a Combination of Near-UV Circular Dichroism and Statistical Approach for Comparative Analysis.

Masato Kiyoshi, Taiji Oyama, Hiroko Shibata, Satoko Suzuki, Yuji Higuchi, Kouhei Tsumoto, Akiko Ishii-Watabe

Abstract readComparative Study
In one paragraph

Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Masato KiyoshiDivision of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan.
Taiji OyamaJASCO Corporation, 2967-5 Ishikawamachi, Hachioji, Tokyo 192-8537, Japan.
Hiroko ShibataDivision of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan.ORCID 0009-0002-6708-1637
Satoko SuzukiJASCO Corporation, 2967-5 Ishikawamachi, Hachioji, Tokyo 192-8537, Japan.
Yuji HiguchiJASCO Corporation, 2967-5 Ishikawamachi, Hachioji, Tokyo 192-8537, Japan.
Kouhei TsumotoDepartment of Bioengineering, School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.ORCID 0000-0001-7643-5164
Akiko Ishii-WatabeDivision of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The higher-order structure (HOS) of therapeutic monoclonal antibodies is one of the important quality characteristics in terms of efficacy and safety. However, the HOS of therapeutic monoclonal antibodies has been assessed using low- to medium-resolution spectroscopy. Furthermore, because the analysis of the obtained spectra has been performed by visual evaluation in many cases, their specificity, structural similarity, and statistical significance have not been thoroughly discussed. Therefore, there is an increasing need for advanced, statistically comparable, and highly specific analytical methods for the HOS of therapeutic monoclonal antibodies. Herein, we describe an analytical method for the HOS of therapeutic monoclonal antibodies using a powerful combination of near-UV circular dichroism (CD) and statistical analysis. The obtained near-UV CD spectra of 14 therapeutic monoclonal antibodies were employed for principal component analysis. Moreover, the spectral data were converted into Euclidean distances to perform equivalence tests and significance tests. The results clearly demonstrated that each antibody had a unique near-UV CD spectrum, like a structural fingerprint. All antibodies were judged to be not equivalent to other antibodies and were also judged to be significantly different from other antibodies. Moreover, the equivalence tests were performed on several lots of antibodies, and each lot of the antibodies were judged to be equivalent. We believe that our methods are useful for identity testing and also for comparative analysis of HOS of therapeutic monoclonal antibodies.

Indexed as

Antibodies, MonoclonalCircular DichroismHumansPrincipal Component AnalysisAntibodies, Monoclonal

Identifiers

PMID40494510
PMCPMC12199232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.